Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KBP-7072 (Zifanocycline) MAD Study in Healthy Subjects
NCT02654626Phase 1Completed
- Sponsor
- KBP Biosciences
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of zifanocycline in acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CAP) and Intra-abdominal infection (IAI) (4 cohorts), sponsored by KBP Biosciences. Primary endpoint: Safety and tolerability up to 17 days. Started Oct 2015; status: completed.
02
Drugs
zifanocycline
03
Conditions
acute bacterial skin and skin structure infections (ABSSSI)community-acquired bacterial pneumonia (CAP)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT02654626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654626.